HOUSTON – Langerhans Cell Histiocytosis (LCH) is a rare disease of white blood cells in which an overabundance of abnormal dendritic cells causes damage to the skin, bone, and other organs, according ...

Robin Bankins says the first time she spoke with MSK’s Dr. Eli Diamond about treating her histiocytosis, she trusted him right away. Based a clinical trial conducted at MSK, the FDA has approved the ...

A nationwide team led by researchers at Baylor College of Medicine, Texas Children’s Hospital and UPMC Children's Hospital of Pittsburgh has proposed a major revision to how Langerhans cell ...

Please provide your email address to receive an email when new articles are posted on . Most patients treated with BRAF and MEK inhibitors for histiocytic disorders showed no active disease.

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to cobimetinib for treatment of certain patients of histiocytic neoplasms.

Synchronous primary ovarian and endometrial cancer in recent years: Changes in recent years. This is an ASCO Meeting Abstract from the 2013 ASCO Annual Meeting I. This abstract does not include a full ...

Histiocytic disorders in children are marked by the abnormal proliferation of cells from the mononuclear phagocyte system, which includes dendritic cells, monocytes, and macrophages. These cells, ...

Johannes holds an MSci in Neuroscience from King’s College London, where he worked on projects involving Alzheimer’s disease and Fragile X syndrome. Johannes holds an MSci in Neuroscience from King’s ...

A novel combination therapy resulted in a significant decrease of disease burden in an animal model of LCH. Langerhans cell histiocytosis (LCH) is a rare cancer involving dendritic cells, a type of ...

Histiocytic disorders are a group of disorders arising from an over-production of histiocytic white blood cells called histiocytes. ‘Histiocytosis’, meaning ‘tissue cell’, is a general concept for ...